Prevention

Latest News

COVID-19 Prophylactic Evusheld Not Expected to Neutralize New Omicron XBB.1.5 Variant
COVID-19 Prophylactic Evusheld Not Expected to Neutralize New Omicron XBB.1.5 Variant

January 9th 2023

Evusheld, the only FDA-approved COVID-19 pre-exposure prophylactic, is anticipated to be ineffective against the emerging XBB.1.5 variant.

FMT Cost-Effective for 90% of Recurrent C Difficile Infections
FMT Cost-Effective for 90% of Recurrent C Difficile Infections

September 16th 2022

Texas Judge Rules Employers Shouldn’t Be Required to Cover HIV PrEP
Texas Judge Rules Employers Shouldn’t Be Required to Cover HIV PrEP

September 8th 2022

FDA Lifts Clinical Hold of Lenacapavir for HIV Treatment and Prevention
FDA Lifts Clinical Hold of Lenacapavir for HIV Treatment and Prevention

May 18th 2022

Developing a COVID-19 Antiviral for Treatment and Prevention
Developing a COVID-19 Antiviral for Treatment and Prevention

May 2nd 2022

Video Series
Video Interviews
Podcasts

More News

© 2023 MJH Life Sciences

All rights reserved.